SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer
SPARC/osteonectin expression is reportedly altered in various malignancies. However, little is known regarding to the prognostic value of SPARC in triple-negative breast cancer (TNBC) patients. In this study, immunohistochemistry and immunoreactive scores (IRSs) were used to evaluate SPARC protein expression in primary tumors from 211 TNBC patients with up to 10 years of clinical follow-up data. High SPARC expression (IRS ≥3) was detected in 52.1% of primary tumors. Patients expressing high SPARC levels had worse disease-free survival (DFS) (HR=1.58, 95% CI: 1.01-2.47, P=0.044) and overall survival (OS) (HR=1.74, 95% CI: 1.06-2.85, P=0.029) than patients with lower SPARC levels. Furthermore, high SPARC expression was an independent prognostic factor for both DFS (HR=1.73, 95% CI: 1.10-2.73, P=0.018) and OS (HR=1.90, 95% CI: 1.14-3.16, P=0.014) in TNBC patients. These results suggest that increased SPARC expression may be an indicator of greater aggressiveness, and may serve as a prognostic factor for triple-negative breast cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Oncotarget - 7(2016), 47 vom: 22. Nov., Seite 76628-76634 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu, Anjie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers, Tumor |
|---|
| Anmerkungen: |
Date Completed 26.02.2018 Date Revised 13.11.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.18632/oncotarget.10532 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM262466929 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM262466929 | ||
| 003 | DE-627 | ||
| 005 | 20231224201815.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.10532 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0874.xml |
| 035 | |a (DE-627)NLM262466929 | ||
| 035 | |a (NLM)27421134 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhu, Anjie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2018 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a SPARC/osteonectin expression is reportedly altered in various malignancies. However, little is known regarding to the prognostic value of SPARC in triple-negative breast cancer (TNBC) patients. In this study, immunohistochemistry and immunoreactive scores (IRSs) were used to evaluate SPARC protein expression in primary tumors from 211 TNBC patients with up to 10 years of clinical follow-up data. High SPARC expression (IRS ≥3) was detected in 52.1% of primary tumors. Patients expressing high SPARC levels had worse disease-free survival (DFS) (HR=1.58, 95% CI: 1.01-2.47, P=0.044) and overall survival (OS) (HR=1.74, 95% CI: 1.06-2.85, P=0.029) than patients with lower SPARC levels. Furthermore, high SPARC expression was an independent prognostic factor for both DFS (HR=1.73, 95% CI: 1.10-2.73, P=0.018) and OS (HR=1.90, 95% CI: 1.14-3.16, P=0.014) in TNBC patients. These results suggest that increased SPARC expression may be an indicator of greater aggressiveness, and may serve as a prognostic factor for triple-negative breast cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SPARC | |
| 650 | 4 | |a osteonectin | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a triple-negative breast cancer | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Osteonectin |2 NLM | |
| 650 | 7 | |a SPARC protein, human |2 NLM | |
| 700 | 1 | |a Yuan, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Ruoxi |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Xiaoyan |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Xiuqing |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiayu |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Pin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Binghe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 7(2016), 47 vom: 22. Nov., Seite 76628-76634 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2016 |g number:47 |g day:22 |g month:11 |g pages:76628-76634 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.10532 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2016 |e 47 |b 22 |c 11 |h 76628-76634 | ||